Sign In
Buy TPST
$1.27
-0.0400 (-3.05%)
At Close: Jun 03, 2026
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
04:47pm, Wednesday, 04'th Feb 2026
BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeutic
Tempest Therapeutics (NASDAQ:TPST) Shares Scheduled to Split on Friday, January 30th
01:20am, Thursday, 22'nd Jan 2026
Tempest Therapeutics, Inc. (NASDAQ: TPST)'s stock is scheduled to split before the market opens on Friday, January 30th. The 2-1 split was recently announced. The newly issued shares will be payable t
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
05:20pm, Tuesday, 20'th Jan 2026
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated th
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants $4.25 million upfront with up to an addi
BRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated th
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
09:00am, Wednesday, 19'th Nov 2025
All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T program Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR ⍺ Antagonist, Phase 3-ready) and TPST-
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
08:30am, Wednesday, 05'th Nov 2025
BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated th
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
04:12pm, Monday, 11'th Aug 2025
BRISBANE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated th
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
08:00am, Monday, 30'th Jun 2025
BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated th
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
08:00am, Wednesday, 11'th Jun 2025
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated th
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
12:36pm, Friday, 06'th Jun 2025
Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
08:00am, Thursday, 05'th Jun 2025
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory designa
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
04:28pm, Tuesday, 13'th May 2025
BRISBANE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutic
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
04:05pm, Monday, 28'th Apr 2025
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
08:00am, Monday, 21'st Apr 2025
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeut
